Identification of a serum-detectable metabolomic fingerprint potentially correlated with the presence of micrometastatic disease in early breast cancer patients at varying risks of disease relapse by traditional prognostic methods

Annals of Oncology

Volumn 22, Issue 6, 2011, Pages 1295-1301

  Oakman, C ^a   Tenori, L ^b,c   Claudino, W M ^a   Cappadona, S ^a   Nepi, S ^b,c   Battaglia, A ^a   Bernini, P ^b   Zafarana, E ^a   Saccenti, E ^b   Fornier, M ^d   Morris, P G ^d   Biganzoli, L ^a   Luchinat, C ^b   Bertini, I ^b   Di Leo, A ^a  

^a ISTITUTO TOSCANO TUMORI   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c FiorGen Foundation   (Italy)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Breast cancer; Metabolomics; Micrometastasis; Prognosis

Indexed keywords

ADULT; ARTICLE; BREAST CANCER; CANCER MORTALITY; CANCER PATIENT; CANCER RELAPSE; CANCER RISK; CLINICAL ARTICLE; COMPUTER PROGRAM; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; EARLY CANCER; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; METABOLOMICS; METASTASIS POTENTIAL; MICROMETASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; ONLINE SYSTEM; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; SENSITIVITY AND SPECIFICITY;

EID: 79957798468     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq606     Document Type: Article

References (53)

1. Bonadonna G, Moliterni A, Zambetti M. et al. 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. BMJ 2005; 330: 217.
2. Paik S, Shak S, Tang G. et al. Expression of the 21 genes in the recurrence score assay and tamoxifen clinical benefit in the NSABP study B-14 of node negative, estrogen receptor positive breast cancer. J Clin Oncol 2005; 23: S(Abstr 510).
3. van de Vijver MJ, He YD, van't Veer LJ. et al. A gene expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347: 1999-2009.
4. Braun S, Naume B. Circulating and disseminated tumor cells. J Clin Oncol 2005; 23: 1623-1626.
5. Janni W, Rack B, Schindlbeck C. et al. The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence. Cancer 2005; 103: 884-891.
6. Braun S, Vogl FD, Naume B. et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 2005; 353: 793-802.
7. Cristofanilli M, Budd GT, Ellis MJ. et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004; 351: 781-791.
8. Hayes DF, Cristofanilli M, Budd GT. et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res 2006; 12: 4218-4224.
9. Stathopoulou A, Vlachonikolis I, Mavroudis D. et al. Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance. J Clin Oncol 2002; 20: 3404-3412.
10. Xenidis N, Vlachonikolis I, Mavroudis D. et al. Peripheral blood circulating cytokeratin-19 mRNA-positive cells after the completion of adjuvant chemotherapy in patients with operable breast cancer. Ann Oncol 2003; 14: 849-855.
11. Harris L, Fritsche H, Mennel R. et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007; 25: 5287-5312.
12. Nicholson J. Global systems biology, personalized medicine and molecular epidemiology. Mol Syst Biol 2006; 2: 52.
13. Claudino W, Quattrone A, Biganzoli L. et al. Metabolomics: available results, current research projects in breast cancer, and future applications. J Clin Oncol 2007; 19: 2840-2846.
14. Boros LG, Cascante M, Lee W- NP. Metabolic profiling of cell growth and death in cancer: applications in drug discovery. Drug Discov Today 2002; 7: 364-372.
15. Griffin J, Shockcor J. Metabolic profiles of cancer cells. Nat Rev Cancer 2004; 4: 551-561.
16. Cheng LL, Lean CL, Bogdanova A. et al. Enhanced resolution of proton NMR spectra of malignant lymph nodes using magic angle spinning. Magn Reson Med 1996; 36: 653-658.
17. Cheng LL, Burns MA, Taylor JL. et al. Metabolic characterization of human prostate cancer with tissue magnetic resonance spectroscopy. Cancer Res 2005; 65: 3030-3034.
18. Sreekumar A, Poisson L, Rajendiran T. et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009; 457: 910-914.
19. Denkert C, Budczies J, Weichert W. et al. Metabolite profiling of human colon carcinoma-deregulation of TCA cycle and amino acid turnover. Mol Cancer 2008; 7: 72.
20. Ippolito J, Xu J, Jain S. et al. An integrated functional genomics and metabolomics approach for defining poor prognosis in human neuroendocrine cancers. Proc Natl Acad Sci USA 2005; 102: 9901-9906.
21. Fossel ET, Carr JM, McDonagh J. Detection of malignant tumors. Watersuppressed proton nuclear magnetic resonance spectroscopy of plasma. N Engl J Med 1986; 315: 1369-1376.
22. Odunsi K, Wollman RM, Ambrosome CB. et al. Detection of epithelial ovarian cancer using 1H-NMR-based metabonomics. Int J Cancer 2005; 113: 782-788.
23. Yang J, Xu G, Zheng Y. et al. Diagnosis of liver cancer using HPLC-based metabonomics avoiding false-positive result from hepatitis and hepatocirrhosis diseases. J Chromatogr B Analyt Technol Biomed Life Sci 2004; 813: 59-65.
24. Bathen TF, Engan T, Krane J, Axelson D. Analysis and classification of proton NMR spectra of lipoprotein fractions from healthy volunteers and patients with cancer or CHD. Anticancer Res 2000; 20: 2393-2408.
25. Kind T, Tolstikov V, Fiehn O, Weiss RH. A comprehensive urinary metabolomic approach for identifying kidney cancer. Anal Biochem 2007; 363: 185-195.
26. Aboagye E, Bhujwalla Z. Malignant transformation alters membrane choline metabolims of human mammary epithelial cells. Cancer Res 1999; 59: 80-84.
27. Whitehead T, Monzavi-Karbassi B, Jousheghany F. et al. 1H-NMR metabolic markers of malignancy correlate with spontaneous metastases in a murine mammary tumor model. Int J Oncol 2005; 27: 257-263.
28. Yang C, Richardson A, Smith J, Osterman A. Comparative metabolomics of breast cancer. Pac Symp Biocomput 2007: 181-192.
29. Belouche-Babari M, Jackson L, Al-Saffar. et al. Identification of magnetic resonance detectable metabolic changes associated with inhibition of phosphoinositide 3-kinase signalling in human breast cancer cells. Mol Cancer Ther 2006; 5: 187-196.
30. Katz-Brul R, Seger D, Rivenson-Segal D. et al. Metabolic markers of breast cancer: enhanced choline metabolism and reduced choline-ether-phospholipid synthesis. Cancer Res 2002; 62: 1966-1970.
31. Sitter B, Lundgren S, Bathen T. et al. Comparison of HRMASMR spectroscopic profiles of breast cancer tissue with clinical parameters. NMR Biomed 2006; 19: 30-40.
32. Cheng LL, Chang IW, Smith BL. et al. Evaluating human breast ductal carcinomas with high-resolution magic-angle spinning proton magnetic resonance spectroscopy. J Magn Reson 1998; 135: 194-202.
33. Mackinnon WB, Barry PA, Malycha PL. et al. Fine-needle biopsy specimens of benign breast lesions distinguished from invasive cancer ex vivo with proton MR spectroscopy. Radiology 1997; 204: 661-666.
34. Mountford CE, Somorjai RL, Malycha P. et al. Diagnosis and prognosis of breast cancer by magnetic resonance spectroscopy of fine needle aspirates analysed using a statistical classification strategy. Br J Surg 2001; 88: 1234-1240.
35. Bollard ME, Stanley EG, Lindon JC. et al. NMR-based metabonomic approaches for evaluating physiological influences on biofluid composition. NMR Biomed 2005; 18: 143-162.
36. Assfalg M, Bertini I, Colangiuli D. et al. Evidence of different metabolic phenotypes in humans. Proc Natl Acad Sci USA 2008; 105: 1420-1424.
37. Griffin JL. Metabonomics: NMR spectroscopy and pattern recognition analysis of body fluids and tissues for characterisation of xenobiotic toxicity and disease diagnosis. Curr Opin Chem Biol 2003; 7: 648-654.
38. Wishart DS, Tzur D, Knox C. et al. HMDB: the Human Metabolome Database. Nucleic Acids Res 2007; 35: D521-D526.
39. Bertini I, Calabro' A, De Carli V. et al. The metabonomic signature of celiac disease. J Proteome Res 2009; 8: 170-177.
40. Trygg J, Wold S. Orthogonal projections to latent structures (O-PLS). J Chemom 2002; 16: 119-128.
41. Vapnik VN. The Nature of Statistical Learning Theory. New York: Springer-Verlag 1995.
42. Westerhuis J, Hoefsloot H, Suzanne Smit S. et al. Assessment of PLSDA cross validation. Metabolomics 2008; 4: 81-89.
43. Altman DG, Bland JM. Diagnostic tests. 1: sensitivity and specificity. BMJ 1994; 308: 1552.
44. Ihaka R, Gentleman RR. R: a language for data analysis and graphics. J Comput Graph Stat 1996; 5: 299-314.
45. Ravdin PM, Siminoff LA, Davis GJ. et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001; 19: 980-991.
46. Olivotto I, Bajdik C, Ravdin P. et al. Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 2005; 23: 2716-2725.
47. Goldstein L, Gray R, Badve S. et al. Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol 2008; 26: 4063-4071.
48. Buyse M, Loi S, van't Veer L. et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 2006; 98: 1183-1192.
49. Baker D, Masterson T, Pace R. et al. The influence of the surgical wound on local tumor recurrence. Surgery 1989; 106: 525-532.
50. Hofer S, Shrayer D, Reichner J. et al. Wound-induced tumor progression: a probable role in recurrence after tumor resection. Arch Surg 1998; 133: 383-389.
51. Taglibue E, Agresti R, Carcangui M. et al. Role of HER2 in wound-induced breast carcinoma proliferation. Lancet 2003; 362: 527-533.
52. Cole WH. The increase in immunosuppression and its role in the development of malignant lesions. J Surg Oncol 1985; 30: 139-144.
53. Fisher B, Gunduz N, Coyle J. et al. Presence of a growth-stimulating factor in serum following primary tumor removal in mice. Cancer Res 1989; 49: 1996-2001.